For U.S. healthcare professionals only

I unleash uncontrolled mast cell proliferation and activation in patients with systemic mastocytosis (SM). My clinical consequences can range from skin lesions, anaphylaxis, and diarrhea, to organ damage and shortened overall survival.3-11

My greatest strength is my ability to hide, as I am often undetected by low-sensitivity diagnostic assays.12

Are you missing me in your practice?

Learn about KIT D816V in SM

For illustrative purposes only. Not an actual patient.

For illustrative purposes only. Not an actual patient.

I unleash uncontrolled mast cell proliferation and activation in patients with systemic mastocytosis (SM). My clinical consequences can range from skin lesions, anaphylaxis, and diarrhea, to organ damage and shortened overall survival.3-11

My greatest strength is my ability to hide, as I am often undetected by low-sensitivity diagnostic assays.12

Are you missing me in your practice?

Learn about KIT D816V in SM

Get clues for identifying systemic mastocytosis and finding KIT D816V

See how KIT D816V acts as the central driver of this mast cell neoplasm.

KIT D816V in SM

Learn how to recognize the hallmark symptoms driven by KIT D816V in systemic mastocytosis.

Suspect SM

Find information on diagnosing systemic mastocytosis and the role of high-sensitivity KIT D816V testing.

Diagnose SM

Get clues for identifying systemic mastocytosis and finding KIT D816V

See how KIT D816V acts as the central driver of this mast cell neoplasm.

KIT D816V in SM

Learn how to recognize the hallmark symptoms driven by KIT D816V in systemic mastocytosis.

Suspect SM

Find information on diagnosing systemic mastocytosis and the role of high-sensitivity KIT D816V testing.

Diagnose SM
  1. Garcia-Montero AC, et al. Blood. 2006;108(7):2366-2372.
  2. Verstovsek S. Eur J Haematol. 2013;90(2):89-98.
  3. Gilreath JA, et al. Clin Pharmacol. 2019;11:77-92.
  4. Metcalfe DD. Blood. 2008;112(4):946-956.
  5. Theoharides TC, et al. N Engl J Med. 2015;373(2):163-172.
  6. Hartmann K, et al. J Allergy Clin Immunol. 2016;137(1):35-45.
  7. Shomali W, Gotlib J. Hematology Am Soc Hematol Educ Program. 2018(1):127-136.
  8. Lim KH, et al. Blood. 2009;113(23):5727-5736.
  9. Kibsgaard L, et al. Derm. 2020;6:294-300.
  10. Sperr WR, et al. Lancet Haematol. 2019;6(12):e638-e649.
  11. Trizuljak J, et al. Allergy. 2020;75(8):1927-1938.
  12. Arock M, et al. Leukemia. 2015;29(6):1223-1232.
  13. Hermine O, et al. PLoS One. 2008;3(5):e2266.
  14. Chatterjee A, et al. Oncotarget. 2015;6(21):18250-18264.
  15. Arber DA, et al. Blood. 2016;127(20):2391-2405.
  16. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev 4th ed. International Agency for Research on Cancer (IARC); 2017.
  17. da Silva EZ, et al. J Histochem Cytochem. 2014;62:698-738.
  18. Valent P, et al. Blood. 2017;129(11):1420-1427.
  19. Jennings SV, et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
  20. Amin K. Respir Med. 2012;106(1):9-14.
  21. Gulen T, et al. J Intern Med. 2016;279(3):211-228.
  22. Mickys U, et al. Dig Liver Dis. 2007;39(7):693-697.
  23. Akin C, Castells M; World Allergy Organization. July 2011. Updated March 2017. Accessed October 9, 2020.  https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/mastocytosis-where-are-we-now.
  24. Pardanani A, et al. Blood. 2010;115(1):150-151.
  25. Pardanani A. Am J Hematol. 2013;88(7):612-624.
  26. Data on file. Blueprint Medicines Corporation. Cambridge, MA. 2020.
  27. Kristensen T, et al. Am J Hematol. 2014;89(5):493-498.
  28. van Anrooij B, et al. Allergy. 2016;71(11):1585-1593.
  29. Vos B, et al. J Allergy Clin Immunol Pract. 2017;5(5):1264-1271.
  30. Berezowska S, et al. Mod Pathol. 2014;27(1):19-29.
  31. Gulen T, et al. J Allergy Clin Immunol Pract. 2017;5:1248-1255.
  32. Hahn HP, Hornick JL. Am J Surg Pathol. 2007;31(11):1669-1676.
  33. Craig JW, et al. Mod Pathol. 2020;133(6):1135-1145.
  34. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Systemic Mastocytosis V.1.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  35. Pardanani A. Am J Hematol. 2019;94(3):363-377.
  36. Akin C, Valent P. Immunol Allergy Clin North Am. 2014;34(2):207-218.
  37. Valent P, et al. Int J Mol Sci. 2019;20(12):2976.
  38. Akin C. J Mol Diagn. 2006;8(4):412-419.

This website is intended for U.S. healthcare professionals only. This website does not provide medical advice and is for educational purposes only.

Blueprint Medicines and associated logo are trademarks of Blueprint Medicines Corporation.

All other trademarks are the property of their respective owners.

© 2021 Blueprint Medicines Corporation.

04/2021     USBP-PRSM-20.011.3

UncoverKIT and the information contained in this site are intended for U.S. healthcare professionals only.

By continuing, you confirm that you are a U.S. healthcare professional.

CONFIRM

You are about to leave UncoverKIT.com

You will enter a website that is not owned or controlled by Blueprint Medicines. Blueprint Medicines is not responsible for any information, statements, or other content you may encounter on third-party websites and makes no representation as to the accuracy of information contained on websites we do not own or control. Further, Blueprint Medicines does not recommend nor endorse the content of any third-party website. Your use of a third-party website is subject of the terms and conditions of use for such sites.

Go back